Epizyme

US Oncology Research, Epizyme collaborate

Wednesday, August 2, 2017

Epizyme, a clinical-stage biopharmaceutical company creating novel epigenetic therapies, and US Oncology Research, one of the nation’s largest networks of independent, community-based oncology practices dedicated to advancing high-quality treatments through clinical trials, announced a collaboration to screen and identify relapsed or refractory follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) patients with EZH2 mutations. Once identified, eligible candidates will be directed to Epizyme’s ongoing phase II clinical trial of tazemetostat, the company’s first-in-class EZH2 inhibitor, as a single-agent treatment for relapsed or refractory patients with FL or DLBCL.

[Read More]

Epizyme President of Research and Chief Scientific Officer Robert Copeland to retire

Thursday, March 9, 2017

Epizyme, a clinical-stage biopharmaceutical company creating novel epigenetic therapies, has announced that President of Research and Chief Scientific Officer Robert A. Copeland, Ph.D., will be retiring from Epizyme in the second quarter of 2017 to pursue advisory and other opportunities within the industry. Dr. Copeland has served in his role since 2008, and will remain a key advisor to Epizyme following his transition. The company is executing plans for continued growth of its investigational pipeline, with plans to name its next development candidate in 2017 as part of its goal of delivering three new candidates into the clinic by 2020.

[Read More]

Epizyme receives Fast Track for Tazemetostat in B-cell lymphoma

Tuesday, November 29, 2016

Epizyme, a clinical-stage biopharmaceutical company creating novel epigenetic therapies, has announced advancements in the company’s clinical programs evaluating tazemetostat, its first-in-class EZH2 inhibitor. The FDA has granted tazemetostat Fast Track designation in patients with diffuse large B-cell lymphoma (DLBCL) with EZH2 activating mutations. Additionally, Epizyme is focusing its phase II registration-enabling study in adult patients with genetically-defined solid tumors on those cancers marked by loss of INI1, and has expanded enrollment in the epithelioid sarcoma cohort of the study based on encouraging early activity in this patient population.

[Read More]

Epizyme appoints Matthew Ros chief operating officer

Friday, May 6, 2016

Epizyme, a clinical stage biopharmaceutical company creating novel epigenetic therapies for people with cancer, has expanded its senior leadership team with the addition of Matthew Ros, who joins the company as chief operating officer. In this role, Ros will be responsible for directing and operationalizing Epizyme’s launch readiness efforts for tazemetostat, and will report to Epizyme’s president and chief executive officer, Robert Bazemore.

[Read More]

Epizyme appoints Robert Bazemore president and CEO

Thursday, August 6, 2015

Epizyme, a clinical stage biopharmaceutical R&D company creating novel epigenetic therapeutics for cancer patients, has announced Robert Bazemore will succeed Robert Gould, Ph.D., as president and chief executive officer of Epizyme, effective Sept. 10. Bazemore also will join the Epizyme board of directors. Following the transition, Gould will continue to sit on the board and work as a consultant to the company.

[Read More]